Peptide Contraindication Deep-Dive

A consolidated, evidence-led reference on contraindications and cautions that appear repeatedly in peptide research and clinical pharmacology — not exhaustive, not personalised advice.

Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.

Contraindications and cautions for peptide compounds are scattered through individual monographs, trial documents, and regulatory product labels. This page consolidates the categories that recur — not as personalised advice, but as a research-literacy reference for reading peptide literature carefully. Specific clinical decisions belong with a registered prescriber.

Active or recent malignancy

Several peptide classes invoke mechanisms (angiogenesis, growth-axis modulation, immune suppression) that are theoretically — and in some cases empirically — implicated in tumour biology.

Pro-angiogenic peptides — BPC-157, TB-500, GHK-Cu. VEGFR2-mediated angiogenesis is co-opted by solid tumours for neo-vascularisation. Pharmacological promotion of angiogenesis in a patient with active or recently-treated cancer is a theoretically serious concern. The clinical drug industry has invested heavily in anti-angiogenic agents (bevacizumab, VEGFR2 kinase inhibitors) for exactly this reason. See angiogenesis mechanism map.
GH-axis peptides — CJC-1295, ipamorelin, tesamorelin. Elevated IGF-1 is associated with several cancer incidences in observational epidemiology. The clinical significance for short-term pulsatile GH stimulation is debated; chronic supra-physiological IGF-1 is a recognised concern.
Melanocortin agonists — Melanotan II has been linked in case reports to atypical melanocytic lesions and melanoma. MC1R agonism on dysplastic melanocytes is the hypothesised mechanism. See melanocortin map.
Immune modulators — Thymosin α-1, KPV. Broad immune modulation carries unpredictable risks in patients with treated cancer.

Pregnancy and lactation

Almost no peptide compound on this site has pregnancy or lactation safety data. Where pregnancy data exists (GLP-1 agonists, principally), it generally counsels against use — and licensed labelling reflects this.

GLP-1 / GIP agonists — semaglutide, tirzepatide: labelled to discontinue prior to planned pregnancy due to limited human data and possible adverse developmental effects in animal studies.
Almost everything else — pregnancy is an explicit exclusion criterion in the clinical trial population for every unapproved peptide. Use in pregnancy is, by definition, outside the studied evidence base.

Wilson's disease and copper-peptide concerns

GHK-Cu is a copper tripeptide — the central biological activity depends on the bound copper ion. Patients with Wilson's disease (a genetic disorder of copper metabolism causing copper accumulation in liver, brain, and other tissues) should not receive exogenous copper-bound peptides. The same caution applies to any patient with elevated serum copper or hepatic copper accumulation. GHK-Cu is also relatively contraindicated alongside copper-chelating therapy (penicillamine, trientine).

Immune-mediated conditions

Peptides that modulate immune function carry risks in both immune- suppressed and autoimmune contexts.

Active autoimmune disease — immune-modulating peptides (thymic peptides, KPV, LL-37) have unpredictable effects on autoimmune drivers. Use without immunological monitoring is high-risk.
Active infection — broad NF-κB-modulating peptides may compromise innate antimicrobial defence. See NF-κB inflammation map.
Recent transplantation — immune-modulator peptides interfere with the carefully-titrated immunosuppression of transplant patients and are contraindicated.

Cardiovascular contraindications

Uncontrolled hypertension — PT-141 (bremelanotide) is contraindicated; transient blood-pressure elevation is documented in trials.
Recent myocardial infarction — pro-angiogenic peptides have theoretical concerns around plaque destabilisation; empirical data is limited but the caution is consistent across monographs.
Long-QT syndrome — specific concern for some incretin-class compounds in patients with known QT prolongation.

Renal and hepatic impairment

Clearance of peptide compounds varies by molecule. Fatty-acid- conjugated long-acting agents (semaglutide, tirzepatide) have modest dose adjustments in severe renal impairment. SS-31 (elamipretide) clearance is renal and is constrained in severe impairment. Most unapproved peptides have no characterised clearance pathway in human populations — use in renal or hepatic impairment is outside the studied evidence base.

Concurrent medication concerns

Insulin and sulfonylureas with GLP-1 agonists — additive hypoglycaemia risk; dose reduction of the insulin or sulfonylurea is the labelled approach.
Anti-coagulants with intramuscular peptide administration — increased haematoma and bleeding risk at injection site.
Concurrent VEGF-modulating therapeutics(bevacizumab, sunitinib, etc.) with pro-angiogenic peptides — pharmacological direct conflict.
Copper chelators with GHK-Cu — direct mechanistic conflict.

What this page does not do

This page cannot substitute for a clinician's review of an individual's history and medications. Where any compound discussed on PeptideStacks is being considered for any use, that decision belongs with a registered prescriber who can evaluate contraindications in context. PeptideStacks does not provide personalised contraindication assessment. See: responsible information policy, medical disclaimer.